Back to Journals » Journal of Experimental Pharmacology » Volume 3

Role of calcium in morphine dependence and naloxone-precipitated withdrawal in mice

Authors Seth V, Prerna Upadhyaya P, Moghe, Hakim M

Published 20 February 2011 Volume 2011:3 Pages 7—12

DOI https://doi.org/10.2147/JEP.S15240

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Vikas Seth, Prerna Upadhyaya, Vijay Moghe, Mushtaq Ahmad
Department of Pharmacology, Mahatma Gandhi Medical College, Jaipur, Rajasthan, India

Purpose: To explore the role of calcium in morphine withdrawal syndrome using various agents affecting calcium levels in cytoplasm.
Methods: Mice were rendered dependent on morphine by subcutaneous injection of morphine, and withdrawal was induced 4 hours later by injecting the opioid antagonist, naloxone. Mice were observed for 30 minutes for signs of withdrawal, ie, characteristic jumping, hyperactivity, urination, and diarrhea. Various calcium channel blockers were injected intraperitoneally 30 minutes before naloxone to evaluate their influence on the severity of the withdrawal syndrome. We also tested the effect of combination levodopa-carbidopa pretreatment and its interaction with a selective alpha-1 blocker, terazosin, on naloxone-precipitated withdrawal in mice acutely dependent on morphine.
Results: A significant dose-dependent attenuation of naloxone-induced morphine withdrawal syndrome was observed with calcium channel blockers, ie, verapamil 20 mg/kg (P < 0.05) and diltiazem 30 mg/kg (P < 0.01). Combination levodopa-carbidopa pretreatment facilitated the morphine withdrawal syndrome, and this was found to be blocked by terazosin, although not to a statistically significant
(P > 0.05) extent.
Conclusion: The results indicate that calcium plays an important role in the genesis of morphine dependence and withdrawal, and suggest the usefulness of calcium channel blockers in the management of morphine withdrawal syndrome.

Keywords: calcium channel blockers, opioid abstinence, verapamil, diltiazem, nifedipine, levodopa-carbidopa combination

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]